New U.S. Cancer Drug Prices Rise 53% In Five Years -report

The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, a 53% increase from 2017, according to a new report from U.S.

Related Keywords

California ,United States ,America ,Merck Kgaa Tepmetko ,Celgene Idhifa ,Stacie Dusetzina ,Katie Porter ,Joe Biden ,Bristol Myers ,Amgen Inc Lumakras ,Nashville Vanderbilt University Medical Center ,Drug Administration ,Reuters ,Representative Katie Porter ,Inflation Reduction Act ,Vanderbilt University Medical Center ,Pharmaceutical Research ,Takeda Pharmaceutical ,Amgen Inc ,National , ,